The global clinical trials market is projected to grow from $127.16 billion in 2025 to $176.32 billion by 2030, with a CAGR of 6.8%. Growth is driven by AI-enabled trial design, decentralized and virtual trials, precision medicine, and real-world evidence studies. North America leads the market while Asia-Pacific is the fastest-growing region. Strategic consolidation continues with major acquisitions strengthening end-to-end capabilities.

Fortrea (Nasdaq: FTRE), a leading global contract research organization, announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The company reported strong first-quarter 2026 performance with a book-to-bill ratio of 1.15x, marking the third consecutive quarter above 1.1x.

Fortrea, a leading global contract research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered suite of solutions designed to revolutionize clinical trial processes. FIT automates workflows, streamlines oversight, and improves productivity for investigators, clinical trial centers, and research teams. The platform builds on Fortrea's flagship Xcellerate® platform and incorporates AI and machine learning to analyze complex patterns, generate predictive signals, and reduce manual tasks while enabling faster decision-making and risk management.

Fortrea, a leading global clinical research organization, launched Fortrea Intelligent Technology (FIT), an AI-driven solution suite designed to transform clinical trial operations. FIT automates workflows, streamlines oversight, and provides real-time insights to sponsors, research sites, and study teams. Built on the Xcellerate® platform, the solution features three pillars: full lifecycle management, foresight analytics, and AI-powered companion tools to accelerate trial delivery and improve quality.

Fortrea, a leading global clinical research organization, announced the launch of Fortrea Intelligent Technology (FIT), an AI-powered solution designed to automate workflows and streamline clinical trial operations. Built on the Xcellerate® platform, FIT offers three pillars: full lifecycle trial management, data-driven foresight analytics, and AI-powered companion tools to improve trial speed, predictability, and quality for sponsors and research sites.

Grabar Law Office is investigating potential securities fraud and fiduciary breaches for several publicly traded companies, alleging misleading statements and undisclosed business risks that potentially harmed shareholders.

Fortrea announced granting 245,000 restricted stock units (RSUs) to two newly hired employees, with vesting occurring in three equal annual installments starting December 10, 2026.

Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for several publicly traded companies, alleging misleading statements and incomplete disclosures that potentially harmed shareholders.

Fortrea has completed a debt tender offer, purchasing $75.7 million of its outstanding 7.500% Senior Secured Notes due 2030, reducing the principal outstanding from $570 million to $494.3 million.

Law firm Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches for four publicly traded companies, alleging misleading statements and undisclosed material facts that impacted investor interests.

Fortrea, a global contract research organization, will release its third quarter 2025 financial results on November 5, 2025, with a conference call scheduled at 8:00 am ET to review the results and conduct a Q&A session.

Fortrea announced granting 75,000 restricted stock units (RSUs) to a newly hired employee, with vesting occurring in three equal annual installments starting September 12, 2026.